Role of hK2, free PSA, and complexed PSA measurements in the very early detection of prostate cancer. by Lilja, H

Testing new PSA subforms to enhance the accuracy of predicting cancer risk and disease outcome in prostate cancer. by Lilja, H

Biology of prostate-specific antigen by Lilja, H

Biology of prostate-specific antigen. by Lilja, H

Cutpoints in clinical chemistry: time for fundamental reassessment. by Vickers, A, Lilja, H

Editorial comment by Christensson, A, Lilja, H

Editorial comment. by Vickers, A, Lilja, H

Prostate cancer: estimating the benefits of PSA screening. by Vickers, A, Lilja, H

Urological cancer: Time for another rethink on prostate cancer screening. by Vickers, A, Lilja, H

We need a better marker for prostate cancer. How about renaming PSA? by Vickers, A, Lilja, H

Detection of androgen receptor mutations in circulating tumor cells: highlights of the long road to clinical qualification. by Lilja, H, Scher, H

Editorial comment. by Gupta, A, Lilja, H

Predicting prostate cancer many years before diagnosis: how and why? by Vickers, A, Lilja, H

PSA is dead, long live PSA. by Vickers, A, Lilja, H

Editorial Comment by Ulmert, D, Lilja, H

Editorial comment. Association between glomerular filtration rate, free, total, and percent free prostate-specific antigen. by Christensson, A, Lilja, H

Can PSA velocity predict risk of death in men with prostate cancer? by Lilja, H, O'Brien, F

Circulating biomarkers for prostate cancer. by Steuber, T, Helo, P, Lilja, H

Screening for prostate cancer: an update. by Shariat, S, Scardino, P, Lilja, H

Five genetic variants associated with prostate cancer. by Vickers, A, Lilja, H, Scardino, P